P78.03 Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC
Cheng Huang(Army Medical University), Xiuquan Lin(Fujian Medical University), Y. Liu(Guangdong Academy of Medical Sciences), J. Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), X. Li, Hongming Pan(Sir Run Run Shaw Hospital), Yujin Wang(First Affiliated Hospital Zhejiang University), Ying Cheng(Jilin Province Tumor Hospital), X. Liu(Chinese PLA General Hospital), Jianping Xiong(Nanchang University), Wei Shi(Jiangsu Hengrui Medicine (China)), Yuzhou Zhao(Capital Medical University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Jin‐Ji Yang(Guangdong General Hospital), Rui Ma(Xijing Hospital), J. Feng(Hangzhou First People's Hospital), L. Jiang(Shanghai Jiao Tong University), Yun Fan(Chinese Academy of Medical Sciences & Peking Union Medical College), Dongmei Lin(Hebei University of Engineering)
Cited by 0
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k